Christopher O'Brien,James Zangrilli,Tushar Shah,Guy Brusselle,Christopher OBrien
申请号：
US14838503
公开号：
US20160102144A1
申请日:
2015.08.28
申请国别(地区):
US
年份:
2016
代理人:
摘要：
Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising: 1) identifying a patient having moderate to severe eosinophilic asthma, wherein the patient's symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/μL； and 2) administering to said patient a therapeutically effective dose of reslizumab.
